Valneva Updates on ACIP Recommendation for IXCHIQ® Vaccine Against Chikungunya for American Travelers

Valneva SE has announced significant updates regarding its IXCHIQ® vaccine, aimed at preventing chikungunya virus infections. The American Advisory Committee on Immunization Practices (ACIP) has issued new recommendations for travelers. This article highlights these updates, the importance of the vaccine, and what travelers need to know.

Key Updates on IXCHIQ® Vaccine

• ACIP Meeting Date: April 16, 2025
• Vaccine: IXCHIQ® (single-dose vaccine for chikungunya)
• Recommendation for Travelers:
  • Ages 18 and Older: Recommended for those traveling to regions with chikungunya outbreaks.
  • High-Risk Areas: Considered for adults traveling to areas without current outbreaks but at risk for prolonged stays (6 months or more).

Precautionary Measures

• Older Adults (65+):
  • ACIP has issued a precautionary recommendation for this age group due to six reported serious adverse events (SAEs) post-vaccination.
  • These SAEs included hospitalizations among individuals aged between 67 and 86, all of whom had pre-existing health conditions.
  • No direct causal link to IXCHIQ® was established, but further investigation is ongoing.

Context of the Chikungunya Virus

• Transmission: Spread by Aedes mosquitoes, chikungunya can cause severe fever, joint pain, and other debilitating symptoms.
• Global Impact:
  • Since 2004, chikungunya outbreaks have occurred in over 110 countries.
  • Over 3.7 million cases reported in the Americas between 2013 and 2023.
  • The World Health Organization (WHO) identifies chikungunya as a significant public health risk.

Valneva’s Commitment to Safety

• Current Safety Profile: No new serious adverse effects reported globally since January 2025.
• Ongoing Monitoring: Valneva is committed to rigorous post-marketing surveillance and safety reporting to the FDA.
• Dr. Juan Carlos Jaramillo’s Statement: Emphasizes the importance of healthcare providers evaluating vaccination benefits and risks for travelers.

Vaccination Supply and Distribution

• Doses Provided: Approximately 80,000 doses of IXCHIQ® supplied to the U.S., Canada, and Europe.
• Recent Orders:
  • 40,000 doses sent to La Réunion for high-risk populations.
  • 50,000 additional doses ordered to support ongoing vaccination efforts during outbreaks.

Summary

Valneva's IXCHIQ® vaccine remains a crucial tool in combating chikungunya, especially for travelers. The ACIP's updated guidelines reflect a cautious but proactive approach to vaccination, particularly among older adults. Travelers are encouraged to consult healthcare providers about vaccination based on individual health profiles and travel plans.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always do your own research or consult a licensed financial advisor before making investment decisions.